- Home
- NSAI vs NSRX Comparison
NSAI vs NSRX Comparison
Compare NSAI & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSAI | NSRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 38.9M |
| IPO Year | 2026 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NSAI | NSRX |
|---|---|---|
| Price | $9.88 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 18.7K | 14.2K |
| Earning Date | N/A | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $1.98 |
| 52 Week High | $9.88 | $9.50 |
Technical Indicators
Market Signals| Indicator | NSAI | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 49.56 |
| Support Level | N/A | $2.97 |
| Resistance Level | N/A | $3.60 |
| Average True Range (ATR) | 0.01 | 0.26 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 75.00 | 64.84 |
Price Performance
Historical ComparisonAbout NSAI NorthStrive Acquisition Corp I. Class A Ordinary Shares
NorthStrive Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.